Epidemiology and management of antiretroviral-associated cardiovascular disease

Open AIDS Journal

Volumn 9, Issue 1, 2015, Pages 23-37

  Chastain, Daniel B ^a   Henderson, Harold ^b   Stover, Kayla R ^b,c  

^a PHOEBE PUTNEY MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Antiretroviral therapy; Cardiovascular disease; Drug interactions; HIV; Hyperlipidemia; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CD14 ANTIGEN; CD163 ANTIGEN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; GROWTH HORMONE RELEASING FACTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SELECTIN; SIMVASTATIN; TESAMORELIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIVIRAL THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSGLYCEMIA; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIPODYSTROPHY; OBESITY; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SMOKING; THROMBOCYTE ACTIVATION;

EID: 84926335940     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601509010023     Document Type: Article

References (230)

1. [1] Sepkowitz KA. AIDS-the first 20 years. N Engl J Med 2001; 344: 1764-72.
2. [2] Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145: 397-406.
3. [3] Kaul S, Fishbein MC, Siegel FJ. Cardiac manifestations of acquired immune deficiency syndrome. Am Heart J 1991; 122: 535-44.
4. [4] Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
5. [5] Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr 2011; 57: 245-53.
6. [6] Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17(8): 1179-93.
7. [7] Hagidan C, Meigds JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32(1): 130-9.
8. [8] Klein DB, Leyden WA, Lanfang XU, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIVnegative individuals with access to care. Clin Infect Dis 2015 Jan 16. pii: civ014. [Epub ahead of print].
9. [9] Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201(12): 1788-95.
10. [10] Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004; 148: s19-26.
11. [11] Duprez DA, Nehaus J, Kuller LH, et al. Inflammation, coagulation, and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7(9): e44454.
12. [12] Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48(2): 142-8.
13. [13] Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51(3): 268-73.
14. [14] Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5(10): e203.
15. [15] Armah KA, McGinnis K, Baker J, et al. HIV status, burden of cormorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55(1): 126-36.
16. [16] Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010; 24(6): 789-802.
17. [17] Farrugia PM, Lucariello R, Coppola JT. Human immunodeficiency virus and atherosclerosis. Cardiol Rev 2009; 17: 211-5.
18. [18] Calza L, Pocaterra D, Pavoni M, et al. Plasma levels of VCAM-1, ICAM-1, E-selectin, P-selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. J Acquir Immune Defic Syndr 2009; 50: 430-2.
19. [19] Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001; 98: 10142-7.
20. [20] Paladugu R, Fu W, Conklin BS, et al. HIV Tat protein causes endothelial dysfunction in procine coronary arteries. J Vasc Surg 2003; 38: 549-55.
21. [21] Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199(1): 79-86.
22. [22] Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4(11): e365.
23. [23] Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010; 211(2): 361-70.
24. [24] Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
25. [25] Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-90.
26. [26] Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204(8): 1227-36.
27. [27] Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206(10): 1558-67.
28. [28] Bots ML, Baldassarre D, Simon A, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J 2007; 28(4): 398-406.
29. [29] Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23: 1841-9.
30. [30] Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205(suppl 3); s375-82.
31. [31] Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51(4): 435-47.
32. [32] Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIVinfected women. J Infect Dis 2011; 203(4): 452-63.
33. [33] Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52(7): 569-76.
34. [34] Tesoriero JM, Gieryic SM, Carrascal A, et al. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14(4): 824-35.
35. [35] Savès M, Chene G, Ducimetiere P, et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37(2): 292-8.
36. [36] Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2012; 56(5): 727-34.
37. [37] Grinspoon SK, Grunfeld C, Kotler DP, et al. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS. Circulation 2008; 118: 198-210.
38. [38] Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep 2011; 13: 51-6.
39. [39] Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37(5): 613-27.
40. [40] Sherer R. HIV, HAART, and hyperlipidemia: balancing the effects. J Acquir Immune Defic Syndr 2003; 34(Suppl 2): s123-9.
41. [41] Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-F70.
42. [42] Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIVinfected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189(6): 1056-74.
43. [43] Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12(2): F51-8.
44. [44] Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12(15): F167-73.
45. [45] Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-7.
46. [46] Lu CL, Lin YH, Wong WW, et al. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1- infected patients with hyperlipidemia. J Microbiol Immunol Infect 2011; 44: 258-64.
47. [47] Overton ET, Arathoon E, Baraldi E, et al. Effect of darunavir on lipid profile in HIV-infected patients. HIV Clin Trials 2012; 13(5): 256-70.
48. [48] Galli M, Ridolfo A, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naïve HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29: 21-31.
49. [49] Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011; 25(2): 185-95.
50. [50] Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24(11): 1781-4.
51. [51] Moyle GJ, Orkin C, Fisher M, et al. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir df in hypercholesterolemic HIV-1 infected individuals. PLoS ONE 2015; 10(2): e0116297.
52. [52] van der Valk M, Kastelein JJ, Murphy RL, et al. for the Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15(18): 2407-14.
53. [53] Bernal E, Masiá M, Padilla S, et al. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS 2008; 22(7): 569-75.
54. [54] Lee FJ, Carr A. Tolerability of HIV integrase inhibitors. Curr Opin HIV AIDS 2012; 7: 422-8.
55. [55] Lennox JL, DeJesus E, Berger DS, et al. STARTMRK Investigators. Raltegravir versus Efavirenz regimens in treatmentnaive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55(1): 39-48.
56. [56] Elion R, Cohen C, Gathe J, et al. GS-US-216-0105 Study Team. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS 2011; 25: 1881-6.
57. [57] Rockstroh JK, DeJesus E, Henry K, et al. GS-236-0103 Study Team. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavirboosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 62(5): 483-6.
58. [58] Zolopa A, Sax PE, DeJesus E, et al. GS-US-236-0102 Study Team. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 63(1): 96-100.
59. [59] Stellbrink HJ, Reynes J, Lazzarin A, et al. SPRING-1 Team. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27(11): 1771-8.
60. [60] Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naïve, HIV-1-infected adults treated with dolutegravir vs efavirenz, raltegravir, and ritonavirboosted darunavir-based regimens over 48 weeks. Clin Drug Investig 2015 Jan 31. [Epub ahead of print].
61. [61] Calza L, Masetti G, Piergentili B, et al. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS 2011; 22(1): 43-5.
62. [62] Kalra S, Agrawal N. Diabetes and HIV: current understanding and future perspectives. Curr Diab Rep 2013; 13(3): 419-27.
63. [63] Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84(6): 1932-7.
64. [64] Meininger G, Hadigan C, Rietschel P, et al. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 2002; 76(2): 460-5.
65. [65] Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIVinfected men under antiretroviral therapy. AIDS 2003; 17: 1503-11.
66. [66] Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated Creactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30(1): 113-9.
67. [67] Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep 2012; 9: 206-17.
68. [68] El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviralnaive cohort. HIV Med 2005; 6(2): 114-21.
69. [69] Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165(10): 1179-84.
70. [70] Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
71. [71] Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19: 1375-83.
72. [72] Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21(13): 1739-45.
73. [73] De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31(6): 1224-9.
74. [74] Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
75. [75] Paik IJ, Kotler DP. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 2011; 25(3): 469-78.
76. [76] Cooper DA, Cordery DV, Reiss P, et al. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med 2011; 12(1): 31-9.
77. [77] Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010 Mar 15; 201: 803-13.
78. [78] Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013; 13(7): 587-96.
79. [79] Iloeje UH, Yuan Y, L’italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 37-44.
80. [80] Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45: 1074-81.
81. [81] Thiébaut R, El-Sadr WM, Friis-Moller N, et al. Data Collection of Adverse events of anti-HIV Drugs Study Group. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10(7): 811-23.
82. [82] Behrens G, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Safety 2000; 23: 57-76.
83. [83] Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis 2011; 24: 43-9.
84. [84] Bereziat V, Cervera P, Le Dour C, et al. LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am J Pathol 2011; 179(5): 2443-53.
85. [85] Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis 2013; 13(11): 964-75.
86. [86] Garrabou G, Lopez, S, Moren C, et al. Mitochondrial damage in adipose tissue of untreated HIV-infected patients. AIDS 2011; 25(2): 165-70.
87. [87] Cherry CL, Gahan ME, McArthur JC, et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002; 30: 271-7.
88. [88] Nolan D, Hammond E, Martin A, et al. DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-38.
89. [89] Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14: F25-F32.
90. [90] Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000, 31: 1482-7.
91. [91] Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351(9112): 1328.
92. [92] Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993-2003.
93. [93] d’Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected patients. AIDS 2004; 18(13): 1811-17.
94. [94] Rerkpattanapipat P, Wongpraparut N, Jacobs LE, et al. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000; 160: 602-8.
95. [95] SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation 1998; 9: 829-30.
96. [96] DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
97. [97] Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
98. [98] Monforte AD, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013; 27: 407.
99. [99] Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of Darunavir/ritonavir versus Atazanavir/ritonavir in treatment naïve, HIV Type 1 infected subjects over 48 weeks. AIDS Res Hum Retroviruses 2012; 28: 1184-95.
100. [100] Sabin CA, Worm SW, Weber R, et al. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
101. [101] Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57(3): 245-53.
102. [102] Strategies for Management of Anti-Retroviral Therapy/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-F24.
103. [103] Choi A, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with Abacavir and Tenofovir exposure in HIV-infected persons. AIDS 2011; 25: 1289-98.
104. [104] Martin A, Bloch M, Armin J, et al. STEAL Study Group. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49(10); 1591-01.
105. [105] Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarcation in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11: 130-6.
106. [106] Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25: 1993-2004.
107. [107] Ribaudo HJ, Benson CA, Zheng Y, et al. ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and longterm results from ACTG A001/ALLRT. Clin Infect Dis 2011; 52(7): 929-40.
108. [108] Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA metaanalysis. J Acquir Immune Defic Syndr 2012; 61(4): 441-7.
109. [109] Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 Glaxo- Smith-Kline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51: 20-8.
110. [110] Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53(1): 84-91.
111. [111] Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir and myocardial infarction risk? Program and abstracts of the 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, Massachusetts. Abstract 747LB.
112. [112] Satchell CS, O’Halloran JA, Cotter AG, et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis 2011; 204(8): 1202-10.
113. [113] Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial dysfunction in treatment and suppressed HIVinfected patients. AIDS 2009; 23: 2021-7.
114. [114] Marchetti G, Casana M, Tincati C, et al. Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role? Clin Infect Dis 2008; 47: 1495-6.
115. [115] Martinez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24: F1-9.
116. [116] Dube MP, Cadden JJ. Lipid metabolism in treated HIV infection. Best Pract Res Clin Endocrinol Metab 2011; 25(3): 429-42.
117. [117] Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46(2): 125-33.
118. [118] Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53(8): 807-16.
119. [119] Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24(11): 1697-707.
120. [120] Saumoy M, Sánchez-Quesada JL, Martínez E, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: spiral substudy. Atherosclerosis 2012; 225(1): 200-7.
121. [121] Zhang X, Cao R, Liu R, et al. Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. PLoS One 2014; 13(9): e90856.
122. [122] Friis-Møller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 2007; 45(8): 1082-4.
123. [123] Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIVinfected patients: comparison with observed events in the D:A:D Study. HIV Medicine 2006; 7(4): 218-30.
124. [124] Friis-Moller N, Thiebaut R, Reiss P, et al. D:A:D. study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491-501.
125. [125] Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis 2011; 52: 387-95.
126. [126] Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2013; 58(1): e1-34.
127. [127] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 3rd Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-421.
128. [128] Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013 2014; 63(25 Pt B): 2889-934.
129. [129] American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014; 37(Suppl 1): s14-80.
130. [130] Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis 2012; 205(Suppl 3): s355-61.
131. [131] Lifson AR, Nehaus J, Arribas JR, et al. INSIGHT SMART Study Group. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health 2010; 100(10): 1896-903.
132. [132] Hileman CO, Wohl DA, Tisch DJ, et al. Initiation of an abacavircontaining regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses 2012; 28: 1561-4.
133. [133] Martínez E, D’Albuquerque PM, Llibre JM, et al. for the SPIRAL Trial Group. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26(18): 2315-26.
134. [134] Carey D, Amin J, Boyd M, et al. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65(9): 1878-88.
135. [135] Ucciferri C, Falasca K, Vignale F, et al. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol 2013; 85: 755-9.
136. [136] Mallolas J, Podzamzcer, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009; 51(1): 29-36.
137. [137] Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Def Syndr 2008; 49: s79-85.
138. [138] Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204(8): 1191-201.
139. [139] Campo R, DeJesus E, Bredeek UF, et al. SWIFT: prospective 48- week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013; 56: 1637-45.
140. [140] Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
141. [141] Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1(ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-46.
142. [142] Martínez E, Larrousse M, Lilbre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24(11): 1697-707.
143. [143] MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials 2011; 12(1): 24-36.
144. [144] Autonopoulos AS, Margaritis M, Lee R, et al. Statins as antiinflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18(11): 1519-30.
145. [145] Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101(2): 207-13.
146. [146] Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35(1): 1-10.
147. [147] Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103(15): 1933-5.
148. [148] Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332(8): 481-7.
149. [149] Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
150. [150] Zanni MV, Fitch KV, Feldpausch M, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS 2014; 28: 2061-70.
151. [151] Lipitor (atorvastatin) [package insert]. New York, NY: Pfizer Inc 2012.
152. [152] Mevacor (lovastatin) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2012.
153. [153] Livalo (pitavastatin) [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc 2013.
154. [154] Pravachol (pravastatin) [package insert]. Princeton, NJ: Bristol- Myers Squibb Company 2013.
155. [155] Crestor (rosuvastatin) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP 2012.
156. [156] Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003; 25: 2822-35.
157. [157] Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 434-70.
158. [158] Zocor (simvastatin) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2012.
159. [159] Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002; 41(14): 1195-1211.
160. [160] Zetia (ezetimibe) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc 2012.
161. [161] Ray GM. Antiretroviral and statin drug-drug interactions. Cardiol Rev 2009; 17: 44-7.
162. [162] Milazzo L, Menzaghi B, Corvasce S, et al. Safety of statin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 46(2): 258-60.
163. [163] Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005; 19(10): 1103-5.
164. [164] Strandberg TE, Feely J, Sigurdsson EL. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY Study. Clin Ther 2004; 26: 1821-33.
165. [165] Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004; 49(4): 283-90.
166. [166] Kahn SE, Beard JC, Schwartz MW, et al. Increased B-cell secretory capacity as a mechanism for islet cell adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38: 562-8.
167. [167] Dalton TA, Berry RS. Hepatotoxicity associated with sustainedrelease niacin. Am J Med 1992; 93: 102-4.
168. [168] Dubé MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006; 11(8): 1081-9.
169. [169] Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIVinfected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47(4): 459-66.
170. [170] Wohl DA, Waters D, Simpson RJ, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008; 47(8): 1105-8.
171. [171] Noor MA, Parker RA, O’Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18(16): 2137-44.
172. [172] Kalra S, Kalra B, Agrawal N, et al. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr 2011; 3: 2.
173. [173] Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013; 5(1): 6.
174. [174] Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9.
175. [175] Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284(4): 472-7.
176. [176] van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005; 143(5): 337-46.
177. [177] Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010; 10: 183.
178. [178] Fitch K, Abbara S, Lee H, et al. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS 2012; 26: 587-97.
179. [179] Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-50.
180. [180] Diamant M, Heine RJ. Thiazolidinediones in Type 2 Diabetes Mellitus: current clinical evidence. Drugs 2003; 63: 1373-405.
181. [181] Hoffman RM, Currier JS. Management of antiretroviral treatmentrelated complications. Infect Dis Clin N Am 2007; 21: 103-32.
182. [182] Home PD, Pocock SJ, Beck-Nielsen H, et al. for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis. N Engl J Med 2007; 357(1): 28-38.
183. [183] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-71.
184. [184] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm
185. [185] Tungsiripat M, El-Bejjani D, Rizk N, et al. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses 2011; 27: 295-302.
186. [186] Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7): 1547-54.
187. [187] Joy SV, Rodgers PT, Scales AC. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005; 39: 110-8.
188. [188] Oriot P, Hermans MP, Selvais P, et al. Exenatide improves weight loss insulin sensitivity and beta-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Ann Endocrinol (Paris) 2011; 72: 244-6.
189. [189] Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 2006; 26: 360-74.
190. [190] Goodwin SR, Reeds DN, Royal M, et al. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab 2013; 98(2): 743-51.
191. [191] Nüesch R, Wang Q, Elzi L, et al. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013; 62: 396-404.
192. [192] Chow DC, Souza SA, Chen R, et al. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4(6): 411-6.
193. [193] James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.
194. [194] Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19(1): 5-13.
195. [195] Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001; 4(2): 185-200.
196. [196] Frishman WH. β-Adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther 2013; 18(4): 310-9.
197. [197] Toprol XL (metoprolol succinate) [package insert]. Wilmington, DE: AstraZeneca 2012.
198. [198] Lopressor (metoprolol tartrate) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2013.
199. [199] Inderal (propranolol hydrochloride) [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc 2010.
200. [200] Corgard (nadolol) [package insert]. New York, NY: Pfizer, Inc.; 2013.
201. [201] Tenormin (atenolol) [package insert]. Willmington, DE: AstraZeneca 2005.
202. [202] Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens 2006; 8(1): 53-6.
203. [203] Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens 2005; 7(Suppl 4): 21-6.
204. [204] Glesby MJ, Aberg JA, Kendall MA, et al. Adults AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005; 78(2): 143-53.
205. [205] Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97: 1411-20.
206. [206] Prinivil (lisinopril) [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; 2012.
207. [207] Capoten (Captopril) [package insert]. Spring Valley, NY: Par Pharmaceutical Companies, Inc 2012.
208. [208] Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993; 25(1): 20-58.
209. [209] Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000; 20(2): 130-9.
210. [210] Cozaar (losartan potassium) [package insert]. Whitehouse Station, NJ: Merck and Co., Inc 2013.
211. [211] Atacand (candesartan) [package insert]. Wilmington, DE: AstraZeneca 2013.
212. [212] Avapro (atacand) [package insert]. New York, NY: Bristol-Myers Squibb Sanofi-Synthelabo Partnership 2012.
213. [213] Teventen (eprosartan mesylate) [package insert]. North Chicago, IL: Abbott Laboratories 2012.
214. [214] Benicar (olmesartan medoxomil) [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc 2007.
215. [215] Micardis (telmisartan) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc 2012.
216. [216] Diovan (valsartan) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2012.
217. [217] Lake JE, Currier JS. Switching antiretroviral therapy to minimize metabolic complications. HIV Ther 2010; 4(6): 693-711.
218. [218] Minami R, Yamamoto M, Takahama S, et al. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother 2011; 17: 183-8.
219. [219] Perez-Matute P, Perez-Martinez L, Blanco JR, et al. Minimal effects of darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells. J Infect Chemother 2012; 18: 485-93.
220. [220] Diaz-Delfin J, del Mar Gutiérrez M, Gallego-Escuredo JM, et al. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res 2011; 91: 112-9.
221. [221] Diaz-Delfin J, Domingo P, Mateo MG, et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother 2012; 56: 3369-75.
222. [222] Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013; 29: 256-65.
223. [223] Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA. Neutral actions of raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res 2011; 9: 174-9.
224. [224] Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis 2011; 24: 43-9.
225. [225] Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12-week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45: 286-97.
226. [226] Koutkia P, Canavan B, Breu J, et al. Growth hormone releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 2004; 292(2): 210-8.
227. [227] Egrifta ™ (tesamorelin) [package insert]. Montreal, Quebec, Canada: Theratechnologies, Inc 2014.
228. [228] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357(23): 2359-70.
229. [229] Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010; 53(3): 311-22.
230. [230] Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008; 22(14): 1719-28.